These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11199820)

  • 1. Is there neuroprotection in Parkinson syndrome?
    Riederer P; Sian J; Gerlach M
    J Neurol; 2000 Sep; 247 Suppl 4():IV/8-11. PubMed ID: 11199820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline.
    Gerlach M; Desser H; Youdim MB; Riederer P
    J Neural Transm Suppl; 1996; 48():7-21. PubMed ID: 8988458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical importance of neuroprotection in Parkinson's disease.
    Riederer P; Gille G; Müller T; Przuntek H; Reichmann H; Riess O; Schwartz A; Schwarz J; Vogt T
    J Neurol; 2002 Oct; 249 Suppl 3():III/53-6. PubMed ID: 12522574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel selective MAO-B inhibitor with neuroprotective and anti-Parkinsonian properties.
    Chan HH; Tse MK; Kumar S; Zhuo L
    Eur J Pharmacol; 2018 Jan; 818():254-262. PubMed ID: 29050969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.
    Caslake R; Macleod A; Ives N; Stowe R; Counsell C
    Cochrane Database Syst Rev; 2009 Oct; (4):CD006661. PubMed ID: 19821381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trials of neuroprotection for Parkinson's disease.
    LeWitt PA
    Neurology; 2004 Oct; 63(7 Suppl 2):S23-31. PubMed ID: 15477583
    [No Abstract]   [Full Text] [Related]  

  • 8. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
    Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
    J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's disease. Diagnosis and the initiation of therapy.
    Bhat V; Weiner WJ
    Minerva Med; 2005 Jun; 96(3):145-54. PubMed ID: 16175158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attempts to obtain neuroprotection in Parkinson's disease.
    Olanow CW
    Neurology; 1997 Jul; 49(1 Suppl 1):S26-33. PubMed ID: 9222272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
    Fernandez HH; Chen JJ
    Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment.
    LeWitt PA
    J Neural Transm Suppl; 1994; 43():171-81. PubMed ID: 7884399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current preclinical findings on substances against Parkinson's disease].
    Gerlach M; Riederer P
    Nervenarzt; 2003 Mar; 74 Suppl 1():S2-6. PubMed ID: 12624677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Prog Neurobiol; 2010 Nov; 92(3):330-44. PubMed ID: 20600573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective strategies in Parkinson's disease : an update on progress.
    Mandel S; Grünblatt E; Riederer P; Gerlach M; Levites Y; Youdim MB
    CNS Drugs; 2003; 17(10):729-62. PubMed ID: 12873156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease].
    Kassubek J; Büttner T; Reichmann H; Riederer P; Schulz JB; Wüllner U; Csoti I
    Fortschr Neurol Psychiatr; 2010 Mar; 78 Suppl 1():S34-6. PubMed ID: 20195940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective therapies.
    Simon DK; Standaert DG
    Med Clin North Am; 1999 Mar; 83(2):509-23, viii. PubMed ID: 10093591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective actions of selegiline.
    Ebadi M; Sharma S; Shavali S; El Refaey H
    J Neurosci Res; 2002 Feb; 67(3):285-9. PubMed ID: 11813232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.